

⚠ HIGH ALERT**topotecan (Rx)**

(toh-poh-tee'kan)

Hycamtin*Func. class.:* Antineoplastic, natural; topoisomerase inhibitor*Chem. class.:* Camptothecin analog

ACTION: Antitumor product with topoisomerase-I–inhibitory activity; topoisomerase I relieves torsional strain in DNA by causing single-strand breaks; also causes double-strand DNA damage

USES: Metastatic ovarian cancer after failure of traditional chemotherapy; relapsed small-cell lung cancer; cervical cancer

Unlabeled uses: Non–small-cell lung cancer (NSCLC), rhabdomyosarcoma

CONTRAINDICATIONS: Pregnancy, breastfeeding, hypersensitivity, severe bone marrow depression

Black Box Warning: Neutropenia, bone marrow suppression

Precautions: Children, renal disease, gelatin hypersensitivity, anemia, contraceptive requirements, dehydration, diarrhea, extravasation, herpes, infertility, neutropenia, pulmonary fibrosis, varicella

DOSAGE AND ROUTES**Metastatic carcinoma of the ovary**

• **Adult:** **IV INFUSION** 1.5 mg/m² over 30 min daily × 5 days starting on day 1 of 21-day course × 4 courses

Persistent cervical cancer

• **Adult:** **IV INFUSION** 0.75 mg/m² on days 1, 2, 3 then 50 mg/m² cisplatin **IV** on day 1 then repeat q21days; adjust for toxicity

Relapsed small-cell lung cancer

• **Adult:** **PO** 2.3 mg/m²/day × 5 days then repeat q21days

Hematologic toxicity

• Do not administer subsequent courses until neutrophils recover to >1000 cells/mm³, platelets to >100,000 cells/mm³, and hemoglobin to >9 g/dL

Neutropenia

• Single agent **IV** (ANC <500 cells/mm³): Reduce dose of topotecan to 1.25 mg/m². Alternatively, granulocyte-colony stimulating factor (G-CSF) may be administered, starting at least 24 hr after last dose of topotecan

• Single agent **PO** (ANC <500 cells/mm³ for ≥7 days, or ANC 500–1000 cells/mm³ lasting beyond day 21): Reduce dose of topotecan to 1.9 mg/m²/day, with subsequent dose reductions by 0.4 mg/m²/day if necessary

Thrombocytopenia

• Single agent **IV** (platelets <25,000 cells/mm³ in the previous cycle): Reduce dose to 1.25 mg/m²

• Single agent **PO** (platelets <25,000 cells/mm³): Reduce dose to 1.9 mg/m²/day, with subsequent dose reductions by 0.4 mg/m²/day if necessary

• In combination with **CISplatin IV** (platelets <25,000 cells/mm³ in the previous cycle): Reduce dose to 0.6 mg/m², and further to 0.45 mg/m² if necessary

Neutropenic fever

• Single agent **PO** (ANC <500 cells/mm³ associated with fever or infection): Reduce to 1.9 mg/m²/day, with subsequent dose reductions by 0.4 mg/m²/day if necessary

T